GAA loading, cardiometabolic risk and inflammation
In this open-label trial, we examined the effects of the 10-week supplementation with 3 grams per day of GAA on biomarkers of cardiometabolic risk and inflammation in 20 apparently healthy volunteers (10 men and 10 women; age 22.0 ± 2.3 years). GAA had no significant effects on serum hsCRP, HDL cholesterol, insulin, and triglycerides. Clinical enzymes were mainly unaffected by GAA supplementation. Alkaline phosphatase levels increased after GAA intervention (13.6% corresponding to 9.5 IU/L; p = 0.01), but mean values remained within normal ranges (44–147 IU/L). Supplementation with GAA yielded a statistically significant increase of the mean serum ferritin levels at post-administration (7.5% corresponding to 4.1 µg/L; p = 0.012). We found that supplemental GAA has no significant effects on traditional biomarkers of cardiometabolic risk and inflammation in healthy volunteers. Neither serum hsCRP nor insulin was affected by 10-week GAA administration, with a ratio of triglycerides to HDL cholesterol (an indicator of atherogenic profile) remaining essentially unaffected by the intervention. This implies that there is no major cardiometabolic burden of medium-term GAA intervention in healthy humans.
Ostojic SM, Trivic T, Drid P, Stajer V, Vranes M. Effects of Guanidinoacetic Acid Loading on Biomarkers of Cardiometabolic Risk and Inflammation. Ann Nutr Metab. 2018;72(1):18-20. doi: 10.1159/000484945. Epub 2017 Dec 12. PMID: 29232678.